Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?

× No keyword cloud information.

16 in total

1. Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.

Authors: Fabrice Andre; Kristine Broglio; Lajos Pusztai; Narjiss Berrada; John R Mackey; Jean Marc Nabholtz; Stephen Chan; Gabriel N Hortobagyi
Journal: Oncologist Date: 2010-04-26

2. Sulforaphane sensitizes human breast cancer cells to paclitaxel-induced apoptosis by downregulating the NF-κB signaling pathway.

Authors: Seung-Hyun Kim; Hyun-Jung Park; Dong-Oh Moon
Journal: Oncol Lett Date: 2017-03-29 Impact factor: 2.967

3. Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

Authors: Tao Wang; Shaohua Zhang; Min Zeng; Xinyou Lu; Ge Shen; Shikai Wu; Santai Song; Zefei Jiang
Journal: Med Oncol Date: 2011-01-25 Impact factor: 3.064

4. Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.

Authors: J P M Ayoub; Sh Verma; Su Verma
Journal: Curr Oncol Date: 2012-04 Impact factor: 3.677

5. Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance.

Authors: Aaron Goldman; Sachin Khiste; Elizaveta Freinkman; Andrew Dhawan; Biswanath Majumder; Jayanta Mondal; Anthony B Pinkerton; Elliot Eton; Ragini Medhi; Vineethkrishna Chandrasekar; M Mamunur Rahman; Takaharu Ichimura; Kodaganur S Gopinath; Pradip Majumder; Mohammad Kohandel; Shiladitya Sengupta
Journal: Sci Signal Date: 2019-08-20 Impact factor: 8.192

6. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.

Authors: Dimo Dietrich; Manuel Krispin; Jörn Dietrich; Anne Fassbender; Jörn Lewin; Nadia Harbeck; Manfred Schmitt; Serenella Eppenberger-Castori; Vincent Vuaroqueaux; Frédérique Spyratos; John A Foekens; Ralf Lesche; John W M Martens
Journal: BMC Cancer Date: 2010-06-01 Impact factor: 4.430

7. Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer.

Authors: Nancy Egerton
Journal: P T Date: 2008-09

8. Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy.

Authors: Jae Hong Seo; Hwa Jung Sung; Kyong Hwa Park; In Keun Choi; Sang Cheul Oh; Sang Won Shin; Yeul Hong Kim; Jun Suk Kim; Ae-Ree Kim; Jae-Bok Lee; Bum Hwan Koo
Journal: Invest New Drugs Date: 2008-08-29 Impact factor: 3.850

9. Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer.

Authors: Marta Vallee Cobham; Diana Donovan
Journal: Cancer Manag Res Date: 2009-06-29 Impact factor: 3.989

10. Drug resistance and the role of combination chemotherapy in improving patient outcomes.

Authors: Denise A Yardley
Journal: Int J Breast Cancer Date: 2013-06-24